Junichi Shimizu

机构：Aichi Cancer Center · ORCID：0000-0003-1204-1371

发表论文 195 篇 · 总被引 4294 次 · h-index 35

代表论文

• Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (2023 · Journal of Clinical Oncology · 被引 323)
• Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study (2025 · Journal of Clinical Oncology · 被引 121)
• 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 (2023 · Annals of Oncology · 被引 38)
• Trastuzumab Deruxtecan for ERBB2 -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases (2025 · JAMA Network Open · 被引 20)
• Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study (2022 · The Oncologist · 被引 15)
• The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review (2024 · Frontiers in Oncology · 被引 11)